Taiki Hakozaki
Honkomagome, 1138677, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications
Bleeding risk and diagnostic yield of bronchoscopy in hematologic malignancies: Platelet count as a predictor.
Journal: Respiratory investigation
Published: April 02, 2026
Capturing durable benefits: interpreting six-year treatment-free survival and restricted mean survival time in CheckMate 227.
Journal: Journal of thoracic disease
Published: October 13, 2025
Corrigendum to 'Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)' [Journal of Thoracic Oncology Vol. 20 No. 7 (2025) 912-927].
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 07, 2025
Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer.
Journal: Microbiome
Published: September 02, 2025
Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: January 09, 2025
Corrigendum to 'Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC' [JTO Clinical and Research Reports, Volume 5 Issue 4 (2024) 100659].
Journal: JTO clinical and research reports
Published: January 06, 2025
Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.
Journal: Current problems in cancer
Published: November 08, 2024
Optimizing immunotherapy for lung cancer: integrating genetic alterations and the tumor mutational burden to refine patient selection.
Journal: Translational cancer research
Published: September 17, 2024
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.
Journal: Journal of cachexia, sarcopenia and muscle
Published: March 22, 2024
Dual PD-1/PD-L1 and CTLA-4 inhibition strategies: tailoring immunotherapy for metastatic non-small cell lung cancer.
Journal: Chinese clinical oncology
Published: February 21, 2024
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 10, 2024
Last Updated: 09/26/2026